In 2023, the National Medical Products Administration will approve a total of 40 varieties of innovative drugs for marketing, and the number of drug registration applications accepted and closed will hit a new high in the past five years. With the in-depth implementation of major national science and technology projects for major new drug creation, and the continuous optimization of drug supervision, medical security and other policies, at present, China has independently developed a number of major new drugs, and the quality of people's healthy life has been further improved.
Although there are a lot of innovative drugs in China, and some new molecular structures and independent intellectual property rights have emerged, these new drugs are mainly developed based on the targets and mechanisms of action discovered abroad. Correspondingly, more and more domestic enterprises have gradually possessed standardized laboratory research and clinical research capabilities, but their output is still dominated by generic drugs (me-too) and innovative new drugs in imitation (me-better). In the final analysis, the homogeneity of new drug creation stems from the lack of original theories and technologies. At present, there must be more original innovation of new drugs "from 0 to 1", that is, based on the upstream of new drug creation, we must explore new methods, new strategies, new ideas, new targets and new mechanisms, improve the level of basic research, and better meet the clinical drug needs of the people.
Achievements belong to the past, and the future has a long way to go. New drug development is a systematic project from the laboratory to the hospital, involving multiple policy goals such as drug safety, effectiveness, and affordability, which is time-consuming, costly, and intellectually expensive, and its system is extremely complex. Therefore, to further promote the original innovation of new drugs, medical insurance, medical treatment, and medicine must be coordinated and governed, and all aspects of production, education, research and application must also be integrated and linked, with the aim of fundamentally reversing the situation that China's new drug creation and biomedical industry are controlled by others.
Continue to optimize the focus and methods of support for major national science and technology projects. It is necessary to aim at the forefront of global biomedical technology development, focus on new drugs and related biotechnology, carry out a full-chain and holistic layout, and strengthen basic research and original innovation. Among them, institutions of higher learning and scientific research institutes should consciously assume their responsibilities, encourage scientists to undertake the work of people's life and health, take the initiative to connect with the frontier progress and new breakthroughs in life science and biotechnology, and open up new directions for the development of the biomedical industry.
The state's attention and investment in basic scientific research is part of the policy support, and it is equally important to take policy supporting measures such as the green channel for drug review and approval, and the coverage of innovative drugs by medical insurance payment, so as to realize the convergence of science and technology policies, medical insurance policies, regulatory policies, and industrial policies. At the same time, it is necessary to continue to deepen the reform of pharmaceutical education, build a new model of pharmaceutical talent training, and strive to build a team of high-level scientific and technological talents.
In addition, it is necessary to build a grid innovation system with source innovation dominated by universities and scientific research institutes, technological innovation dominated by pharmaceutical enterprises, and close integration of upstream and downstream to accelerate the transfer and transformation of achievements. In particular, enterprises and other business entities should focus on the layout of core industries, open up the basic research innovation chain and the path of clinical transformation and application through multi-party collaboration, strive to build a global innovation platform, and continuously explore the international market. (Author: Hu Yinglian **Economy**).
For more information or cooperation, please pay attention to the official WeChat of China Economic Net (name: China Economic Net, ID: ourcecn).
*:Economy**.